Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T16:38:16.735Z.
Calculation as of: 2026-10-06T16:38:16.735Z.
Quote observation: 2026-10-06T16:35:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 82cee4a6010f8650e239c44e6fa86f6cad5a1cacb0b867e980d6d40a64789328
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Nautilus Biotechnolgy, Inc.
Market Cap
$241.86M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$242.57M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$242.54M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$243.06M
Price/OCF Ratio
N/A
TTM Avg
252.82
3Y Avg
252.82
5Y Avg
155.13
Market Cap
$242.35M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$238.48M
Price/OCF Ratio
N/A
TTM Avg
6.47
3Y Avg
15.02
5Y Avg
16.17
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nautilus Biotechnolgy, Inc. (NAUT) | $241.86M | N/A | N/A | N/A | N/A |
| Invivyd, Inc. (IVVD)vs › | $241.87M | N/A | N/A | N/A | N/A |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $242.57M | N/A | N/A | N/A | N/A |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $242.54M | N/A | N/A | N/A | N/A |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.06M | N/A | 252.82 | 252.82 | 155.13 |
| Galectin Therapeutics Inc. (GALT)vs › | $242.35M | N/A | N/A | N/A | N/A |
| InflaRx N.V. (IFRX)vs › | $238.97M | N/A | N/A | N/A | N/A |
| SIGA Technologies, Inc. (SIGA)vs › | $238.48M | N/A | 6.47 | 15.02 | 16.17 |
| Q32 Bio Inc. (QTTB)vs › | $246.15M | N/A | 8.05 | 8.05 | 8.05 |
| Akebia Therapeutics, Inc. (AKBA)vs › | $238.29M | 5.73 | 7.79 | 7.79 | 7.79 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
